Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 or over~2. Ambulatory while taking 3,4-DAP, i.e. the patient was able to perform the timed up and go (TUG), either with or without an assistive device~3. Established diagnosis of LEMS, with documentation provided~4. Continuous use of Jacobus 3,4-DAP for at least 3 months~5. Minimum of 3 doses per day with no single dose less than 10 mg of 3,4-DAP~6. The patient needed to wait about 15 to 30 minutes to experience an unequivocal improvement in a LEMS-induced dysfunction after they take their first dose of 3,4-DAP in the morning \[a patient who remains in bed past this point by choice may still be eligible\]~7. Stable regimen of all LEMS-related treatments for at least 3 months~8. Stable daily regimen of other medications (prescription and over-the-counter) for a minimum of 1 month~9. Willing to chance being tapered off of 3,4-DAP~10. Fluency in English~11. If applicable, agreed to use birth control during heterosexual intercourse until at least 2 weeks after completion of study~12. A signed informed consent by the study subject~Exclusion Criteria:~1. Last monoclonal antibody treatment (e.g. rituximab) was less than 6 months ago (i.e., recent treatment is an exclusion)~2. Clinically significant or poorly controlled condition that in the opinion of the study personnel might pose an unacceptable risk to the patient if entered into the study~3. Respiratory failure requiring intubation while on 3,4-DAP with no precipitating event or medication~4. Use of any investigational drug other than 3,4-DAP within the last 30 days~5. Pregnant or lactating~6. Current use of other aminopyridines (e.g.4-AP) or guanidine~7. Did not display a sufficiently large response to 3,4-DAP during the baseline observation period in the CRU to detect a decline during withdrawal of 3,4-DAP

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous 3,4-DAP (Type: ACTIVE_COMPARATOR): Subjects continued taking their usual individualized regimen of 3,4-DAP base, 30 to 100 mg daily divided into at least 3 doses.
- Taper 3,4-DAP to Placebo (Type: PLACEBO_COMPARATOR): Subjects were tapered over 3 days from their usual individualized regimen of 3,4-DAP base (30 to 100 mg daily divided into at least 3 doses) to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base

Based on this trial design, predict the completion outcome and termination type (if applicable).